Longenesis provides a digital platform for post-market research and patient engagement that bridges life-science companies, healthcare providers and patients.
Promoting collaboration between biomedical institutions, patient organizations and research partners by identifying biomedical data from metadata files, by onboarding population cohorts and by engaging new patients in the research.
Longenesis and MSD introduce an online test to assess cervical cancer risk. The tool uses proprietary algorithms to analyze user-provided data and deliver personalized risk evaluations. The partnership leverages EIT Health’s support to expand access to early detection solutions.
Longenesis partners with Novartis to develop digital solutions for heart care. The collaboration focuses on integrating advanced technologies into cardiovascular health management. Both companies aim to enhance patient outcomes through digital health innovations.
Latvian biotech firm **Longenesis** receives the Latvian Entrepreneurship Award. The company operates in the biotechnology sector, though specific details about its products, research, or recent developments are not provided in the article.
An EIT Health-backed start-up secures **USD1.2 million in seed funding**. The company, though unnamed in the announcement, operates within the European Institute of Innovation & Technology’s health innovation ecosystem. The funding supports early-stage development of health technologies or solutions.
